Published in Lancet Psychiatry on July 10, 2017
Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? NPJ Schizophr (2017) 0.75
Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl (1998) 2.85
Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry (2016) 2.04
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand (2002) 1.60
Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res (2012) 1.51
Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open (2016) 1.48
Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry (2004) 1.44
Cannabis use and outcome of recent onset psychosis. Eur Psychiatry (2005) 1.42
Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull (2009) 1.30
Reliability of the life chart schedule for assessment of the long-term course of schizophrenia. Schizophr Res (2000) 1.25
Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand (2000) 1.23
Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull (2009) 1.17
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry (2013) 1.16
Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med (2008) 1.12
The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.03
Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry (2007) 0.87
Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res (2010) 0.86
A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Aust N Z J Psychiatry (2013) 0.82
Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry (2013) 0.81
The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med (2015) 0.80
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry (2016) 0.80
Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study. JAMA Psychiatry (2016) 0.78
Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res (2015) 0.78
Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. Trials (2016) 0.78
Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS One (2015) 0.78
Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med (2017) 0.77
Variables associated with nonadherence in clinically stable patients with bipolar disorder. Actas Esp Psiquiatr (2016) 0.77
Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. PLoS One (2016) 0.77
Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophr Res (2016) 0.77
Neural mediator of the schizotypy-antisocial behavior relationship. Transl Psychiatry (2015) 0.75